A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Mexico. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-25.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of 13-valent pneumococcal vaccine in healthy infants given with routine pediatric vaccinations in Mexico.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent pneumococcal conjugate vaccine
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95 percent confidence interval (95% CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35mcg/mL, 1 Month After Dose 2 of the Infant Series
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after dose 2 of the infant series (5 months of age)
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Concentration ≥0.35mcg/mL, 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the toddler dose (13 months of age)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody After Dose 2 of the Infant Series
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.
Time frame: Dose 2 of infant series (4 months of age)
GMC for Serotype-specific Pneumococcal IgG Antibody After Dose 3 of the Infant Series
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.
Time frame: Dose 3 of infant series (6 months of age)
GMC for Serotype-specific Pneumococcal IgG Antibody After the Toddler Dose
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data after the toddler dose and after the third dose of the infant series.
Time frame: Toddler Dose (12 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0cm); Moderate (2.5 to 7.0cm); Severe (greater than \[\>\] 7.0cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 1 of Infant Series (2 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 2 of Infant Series (4 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 3 (6 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after toddler dose (12 months of age)
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (2 Months of Age)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 1 of Infant Series (2 months of age)
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 Months of Age)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 2 of Infant Series (4 months of age)
Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (6 Months of Age)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 3 of Infant Series (6 months of age)
Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 Months of Age)
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after toddler dose (12 months of age)
| Milestone | 13vPnC |
|---|---|
| Started | 225 |
| Vaccinated dose 1 | 223 |
| Vaccinated dose 2 | 214 |
| Vaccinated dose 3 | 194 |
| Completed | 192 |
| Not completed | 33 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Parent/legal guardian request | 6 |
| Withdrew: Failed to return | 2 |
| Withdrew: Other | 19 |
| Milestone | 13vPnC |
|---|---|
| Started | 192 |
| Completed | 191 |
| Not completed | 1 |
| Withdrew: Parent/legal guardian request | 1 |
| Milestone | 13vPnC |
|---|---|
| Started | 191 |
| Completed | 183 |
| Not completed | 8 |
| Withdrew: Parent/legal guardian request | 1 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Failed to return | 4 |
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95 percent confidence interval (95% CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| Percentage of participants | 13vPnC |
|---|---|
| Common serotypes - serotype 4 | 100.0 (97.9 to 100.0) |
| Common serotypes - serotype 6B | 97.7 (94.1 to 99.4) |
| Common serotypes - serotype 9V | 98.2 (94.9 to 99.6) |
| Common serotypes - serotype 14 | 98.8 (95.8 to 99.9) |
| Common serotypes - serotype 18C | 98.8 (95.8 to 99.9) |
| Common serotypes - serotype 19F | 98.2 (95.0 to 99.6) |
| Common serotypes - serotype 23F | 92.9 (87.9 to 96.3) |
| Additional serotypes - serotype 1 | 99.4 (96.8 to 100.0) |
| Additional serotypes - serotype 3 | 94.1 (89.4 to 97.1) |
| Additional serotypes - serotype 5 | 98.2 (95.0 to 99.6) |
| Additional serotypes - serotype 6A | 98.8 (95.8 to 99.9) |
| Additional serotypes - serotype 7F | 98.8 (95.8 to 99.9) |
| Additional serotypes - serotype 19A | 99.4 (96.8 to 100.0) |
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| Percentage of participants | 13vPnC |
|---|---|
| Common serotypes - serotype 4 | 100.0 (98.1 to 100.0) |
| Common serotypes - serotype 6B | 80.9 (74.7 to 86.2) |
| Common serotypes - serotype 9V | 95.9 (92.1 to 98.2) |
| Common serotypes - serotype 14 | 99.0 (96.3 to 99.9) |
| Common serotypes - serotype 18C | 93.3 (88.9 to 96.4) |
| Common serotypes - serotype 19F | 98.5 (95.5 to 99.7) |
| Common serotypes - serotype 23F | 77.9 (71.5 to 83.6) |
| Additional serotypes - serotype 1 | 98.5 (95.6 to 99.7) |
| Additional serotypes - serotype 3 | 96.4 (92.7 to 98.5) |
| Additional serotypes - serotype 5 | 97.4 (94.1 to 99.2) |
| Additional serotypes - serotype 6A | 94.9 (90.8 to 97.5) |
| Additional serotypes - serotype 7F | 99.0 (96.3 to 99.9) |
| Additional serotypes - serotype 19A | 99.5 (97.2 to 100.0) |
Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| Percentage of participants | 13vPnC |
|---|---|
| Common serotypes - serotype 4 | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 6B | 99.4 (96.5 to 100.0) |
| Common serotypes - serotype 9V | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 18C | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 19F | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 23F | 99.4 (96.5 to 100.0) |
| Additional serotypes - serotype 1 | 100.0 (97.6 to 100.0) |
| Additional serotypes - serotype 3 | 96.7 (92.5 to 98.9) |
| Additional serotypes - serotype 5 | 100.0 (97.6 to 100.0) |
| Additional serotypes - serotype 6A | 100.0 (97.6 to 100.0) |
| Additional serotypes - serotype 7F | 100.0 (97.6 to 100.0) |
| Additional serotypes - serotype 19A | 100.0 (97.6 to 100.0) |
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.
| mcg/mL | 13vPnC |
|---|---|
| Common serotypes - serotype 4 | 3.54 (3.16 to 3.97) |
| Common serotypes - serotype 6B | 0.84 (0.71 to 0.98) |
| Common serotypes - serotype 9V | 1.82 (1.60 to 2.08) |
| Common serotypes - serotype 14 | 5.54 (4.72 to 6.50) |
| Common serotypes - serotype 18C | 1.80 (1.56 to 2.07) |
| Common serotypes - serotype 19F | 4.14 (3.59 to 4.78) |
| Common serotypes - serotype 23F | 0.84 (0.71 to 0.99) |
| Additional serotypes - serotype 1 | 3.41 (3.00 to 3.89) |
| Additional serotypes - serotype 3 | 1.11 (1.01 to 1.23) |
| Additional serotypes - serotype 5 | 1.89 (1.67 to 2.13) |
| Additional serotypes - serotype 6A | 1.86 (1.60 to 2.16) |
| Additional serotypes - serotype 7F | 2.98 (2.70 to 3.29) |
| Additional serotypes - serotype 19A | 3.52 (3.07 to 4.03) |
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw.
| mcg/mL | 13vPnC |
|---|---|
| Common serotypes - serotype 4 | 3.48 (3.12 to 3.88) |
| Common serotypes - serotype 6B | 5.02 (4.27 to 5.90) |
| Common serotypes - serotype 9V | 2.34 (2.11 to 2.60) |
| Common serotypes - serotype 14 | 9.35 (8.07 to 10.82) |
| Common serotypes - serotype 18C | 2.50 (2.23 to 2.81) |
| Common serotypes - serotype 19F | 3.75 (3.28 to 4.29) |
| Common serotypes - serotype 23F | 1.83 (1.55 to 2.17) |
| Additional serotypes - serotype 1 | 4.23 (3.73 to 4.79) |
| Additional serotypes - serotype 3 | 1.17 (1.03 to 1.33) |
| Additional serotypes - serotype 5 | 3.11 (2.75 to 3.52) |
| Additional serotypes - serotype 6A | 4.08 (3.56 to 4.68) |
| Additional serotypes - serotype 7F | 3.71 (3.34 to 4.12) |
| Additional serotypes - serotype 19A | 4.19 (3.71 to 4.74) |
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data after the toddler dose and after the third dose of the infant series.
| mcg/mL | 13vPnC |
|---|---|
| Common serotypes - serotype 4 | 5.10 (4.41 to 5.89) |
| Common serotypes - serotype 6B | 15.41 (12.92 to 18.38) |
| Common serotypes - serotype 9V | 3.76 (3.29 to 4.29) |
| Common serotypes - serotype 14 | 10.62 (9.16 to 12.32) |
| Common serotypes - serotype 18C | 3.93 (3.45 to 4.48) |
| Common serotypes - serotype 19F | 11.33 (9.68 to 13.26) |
| Common serotypes - serotype 23F | 5.70 (4.81 to 6.77) |
| Additional serotypes - serotype 1 | 5.86 (5.08 to 6.75) |
| Additional serotypes - serotype 3 | 1.62 (1.42 to 1.84) |
| Additional serotypes - serotype 5 | 4.75 (4.18 to 5.40) |
| Additional serotypes - serotype 6A | 11.64 (9.93 to 13.64) |
| Additional serotypes - serotype 7F | 5.81 (5.18 to 6.51) |
| Additional serotypes - serotype 19A | 8.95 (7.84 to 10.23) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0cm); Moderate (2.5 to 7.0cm); Severe (greater than \[\>\] 7.0cm). Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Tenderness: Any | 63.5 |
| Tenderness: Significant | 12.4 |
| Swelling: Any | 31.2 |
| Swelling: Mild | 25.1 |
| Swelling: Moderate | 11.9 |
| Swelling: Severe | 0 |
| Redness: Any | 33.8 |
| Redness: Mild | 27.9 |
| Redness: Moderate | 10.6 |
| Redness: Severe | 0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Tenderness: Any | 69.4 |
| Tenderness: Significant | 12.6 |
| Swelling: Any | 29.9 |
| Swelling: Mild | 20.0 |
| Swelling: Moderate | 13.3 |
| Swelling: Severe | 0 |
| Redness: Any | 28.9 |
| Redness: Mild | 19.5 |
| Redness: Moderate | 12.3 |
| Redness: Severe | 0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Tenderness: Any | 61.3 |
| Tenderness: Significant | 15.4 |
| Swelling: Any | 29.4 |
| Swelling: Mild | 19.0 |
| Swelling: Moderate | 14.6 |
| Swelling: Severe | 0 |
| Redness: Any | 31.8 |
| Redness: Mild | 20.9 |
| Redness: Moderate | 13.9 |
| Redness: Severe | 0 |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0cm); Moderate (2.5 to 7.0cm); Severe (\>7.0cm). Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Tenderness: Any | 43.7 |
| Tenderness: Significant | 3.8 |
| Swelling: Any | 21.3 |
| Swelling: Mild | 8.1 |
| Swelling: Moderate | 15.8 |
| Swelling: Severe | 0 |
| Redness: Any | 22.0 |
| Redness: Mild | 8.8 |
| Redness: Moderate | 15.7 |
| Redness: Severe | 0 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Fever ≥38 degrees C but ≤39 degrees C | 7.0 |
| Fever >39 degrees C but ≤40 degrees C | 0 |
| Fever >40 degrees C | 0 |
| Decreased appetite | 31.0 |
| Irritability | 69.8 |
| Increased sleep | 37.2 |
| Decreased sleep | 32.8 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Fever ≥38 degrees C but ≤39 degrees C | 18.5 |
| Fever >39 degrees C but ≤40 degrees C | 0.6 |
| Fever >40 degrees C | 0 |
| Decreased appetite | 29.3 |
| Irritability | 62.2 |
| Increased sleep | 24.5 |
| Decreased sleep | 35.1 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Fever ≥38 degrees C but ≤39 degrees C | 18.3 |
| Fever >39 degrees C but ≤40 degrees C | 2.2 |
| Fever >40 degrees C | 0 |
| Decreased appetite | 25.7 |
| Irritability | 63.2 |
| Increased sleep | 22.9 |
| Decreased sleep | 37.3 |
Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of participants | 13vPnC |
|---|---|
| Fever ≥38 degrees C but ≤39 degrees C | 23.0 |
| Fever >39 degrees C but ≤40 degrees C | 0 |
| Fever >40 degrees C | 0 |
| Decreased appetite | 33.8 |
| Irritability | 46.7 |
| Increased sleep | 17.9 |
| Decreased sleep | 22.0 |
Collected over Baseline through 1 Month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=2 months of age; Dose 2=4 months of age; Dose 3=6 months of age; Toddler Dose=12 months of age.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infant Series 13vPnC | — | 3/223 (1.3%) | 182/223 (81.6%) |
| After the Infant Series 13vPnC | — | 3/223 (1.3%) | 3/223 (1.3%) |
| Toddler Dose 13vPnC | — | 2/191 (1%) | 96/191 (50.3%) |
| Event | Infant Series 13vPnC | After the Infant Series 13vPnC | Toddler Dose 13vPnC |
|---|---|---|---|
| Acute sinusitisInfections and infestations | 0/223 | 0/223 | 1/191 |
| Seizure anoxicNervous system disorders | 0/223 | 0/223 | 1/191 |
| MyocarditisCardiac disorders | 1/223 | 0/223 | 0/191 |
| DiarrhoeaGastrointestinal disorders | 1/223 | 0/223 | 0/191 |
| PyrexiaGeneral disorders | 1/223 | 1/223 | 0/191 |
| BronchiolitisInfections and infestations | 1/223 | 0/223 | 0/191 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/223 | 0/223 | 0/191 |
| Kawasaki's diseaseVascular disorders | 1/223 | 0/223 | 0/191 |
| PneumoniaInfections and infestations | 0/223 | 1/223 | 0/191 |
| Breath holdingPsychiatric disorders | 0/223 | 1/223 | 0/191 |
| Event | Infant Series 13vPnC | After the Infant Series 13vPnC | Toddler Dose 13vPnC |
|---|---|---|---|
| IrritabilityGeneral disorders | 148/212 | — | 71/152 |
| Tenderness (any)Skin and subcutaneous tissue disorders | 136/196 | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 134/211 | — | 66/151 |
| IrritabilityGeneral disorders | 103/163 | — | — |
| IrritabilityGeneral disorders | 120/193 | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 100/163 | — | — |
| Decreased sleepGeneral disorders | 56/150 | — | — |
| Increased sleepGeneral disorders | 77/207 | — | 25/140 |
| Decreased sleepGeneral disorders | 66/188 | — | — |
| Redness (any)Skin and subcutaneous tissue disorders | 69/204 | — | 31/141 |
| Age Continuous(months) | 13vPnC |
|---|---|
| Mean | 2.1 ± 0.5 |
| Sex: Female, Male(Participants) | 13vPnC |
|---|---|
| Female | 109 |
| Male | 116 |
The record gives a start of Jul 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →